In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist

Xenobiotica

Volumn 42, Issue 12, 2012, Pages 1187-1196

  Takusagawa, Shin ^a   Miyashita, Aiji ^a   Iwatsubo, Takafumi ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cytochrome P450; Drug interaction; Induction; Inhibition; Mirabegron

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCOSE 6 PHOSPHATE; MESSENGER RNA; MIRABEGRON; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OMEPRAZOLE; PHOSPHATE; POTASSIUM; POTASSIUM DIHYDROGEN PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIFAMPICIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME BLOOD LEVEL; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER CELL; LIVER MICROSOME; PROTEIN EXPRESSION;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; NADP; RECOMBINANT PROTEINS; RNA, MESSENGER; THIAZOLES; TIME FACTORS;

EID: 84868627009     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.700140     Document Type: Article

References (24)

1. Babbar S, Chanda S, Bley K. (2010). Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 40:807-816.
2. Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
3. European Medicines Agency. (2010). Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/ docs/en-GB/document- library/Scientific-guideline/2010/05/ WC500090112.pdf. Accessed on 05 Jul 2012.
4. Fahmi OA, Kish M, Boldt S, Obach RS. (2010). Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
5. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
6. Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M. (2011). The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European- Australian Phase III trial. Eur Urol Suppl 10:278-279.
7. Krauwinkel WJ, van Gelderen EM, Groen MJ, Schaddelee M, de Koning P. (2010). An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharmacol Ther 87:S88.
8. LeCluyse EL, Audus KL, Hochman JH. (1994). Formation of extensive canalicular networks by rat hepatocytes cultured in collagensandwich configuration. Am J Physiol 266:C1764-C1774.
9. LeCluyse EL, Bullock PL, Parkinson A, Hochman JH. (1996). Cultured rat hepatocytes, in Pharmaceutical Biotechnology. In: Borchardt RT, Wilson G, Smith P, eds. Models for Assessing Drug Absorption and Metabolism Vol. 8. New York: Plenum Press, 121-159.
10. Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. (1999). Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dispos 27:327-335.
11. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
12. Mudra DR, Parkinson A. (2001). Preparation of hepatocytes; Unit 14.2. In: Maines MD, ed. Current Protocols in Toxicology, Volume 1. New York: John Wiley and Sons, Inc
13. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N. (2011). The efficacy and safety of mirabegron in patients with overactive bladder syndrome - results from a North-American Phase III trial. Eur Urol Suppl 10:278.
14. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
15. Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. (2009). In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 37:2045-2054.
16. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
17. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816.
18. Robertson P, DeCory HH, Madan A, Parkinson A. (2000). In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664-671.
19. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007). Effect of R-2-(2-aminothiazol-4-yl)-4'- {2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647.
20. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T. (2012a). Absorption, metabolism and excretion of [(14 C]mirabegron (YM178), a potent and selective s(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 40:815-824.
21. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T. (2012b). Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)- adrenoceptor agonist. Xenobiotica. [Epub ahead of print ; 18 April 2012].
22. Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080.
23. US FDA, Center for Drug Evaluation and Research (CDER). (2006). Guidance for industry. Drug interaction studies - study design, data analysis, and implications for dosing and labeling. draft guidance
24. US FDA, Center for Drug Evaluation and Research (CDER). (2012). Guidance for industry. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. draft guidance. Yamaguchi O, Chapple CR. (2007). Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752-756.